NEW YORK (GenomeWeb News) - Exact Sciences said today that it has signed a deal with the Mayo Clinic for exclusive rights to intellectual property related to stool-based screening for colorectal cancer.
The company said that it has also closed an $8.2 million private placement of 4.3 million shares of its common stock.
Exact gained exclusive rights to technology developed by the Mayo Clinic's David Ahlquist relating to sample processing, analytical testing, and data analysis for non-invasive, stool-based DNA screening for colorectal cancer.